Morphine

Selected IR oral and IV products manage pain severe enough to require an opioid when alternatives are inadequate. Hikma oral solution 2 and 4 mg/mL includes pediatric use at age two and older; section 8.4 establishes acute, not chronic, pediatric pain. Selected IR tablets establish acute pediatric use at body weight ≥50 kg. ER tablets and capsules address severe persistent pain requiring an opioid when alternatives, including IR opioids, are inadequate; they are not as-needed analgesics and have no established pediatric use below 18.

Duramorph permits IV analgesia and epidural/intrathecal pain management; it is not for continuous microinfusion devices. Infumorph is only for continuous epidural/intrathecal infusion of intractable chronic pain when less invasive methods are inadequate, not single-dose systemic or neuraxial injection. This profile gives selected current U.S. labels, not a universal morphine conversion tool. Other injection devices, IM/SC regimens, compounded preparations and morphine combinations require their own verified orders and labeling.

Use the lowest effective dose and shortest duration consistent with treatment goals; prescribe the exact product. Pediatric chronic-pain regimens are not established by these selected IR labels.

Write both mg and mL and the concentration. Use a metric graduated oral syringe; the 20 mg/mL product requires its enclosed syringe, never a household spoon. The selected pediatric label calculates weight-based mg, converts to mL, rounds volumes below 1 mL to the nearest 0.1 mL and above 1 mL to the nearest 0.2 mL, then recalculates final mg. Confirm the prescribed dose/volume with the pharmacist. Opioid tolerance means at least one week of ≥60 mg/day oral morphine or an explicitly labeled equianalgesic opioid regimen; a past occasional opioid dose is insufficient.

Swallow ER tablets whole. Selected capsules may be opened onto applesauce and swallowed immediately without chewing their pellets; discard unused mixture. Do not substitute other foods. Actavis does not authorize tube delivery; Upsher-Smith describes a gastrostomy procedure and specifically prohibits nasogastric delivery. Use its complete instructions and matched clinical order.

Hikma 1 mL IV syringes (2 or 4 mg/mL) and IV vials (4, 8 or 10 mg/mL): adult initial 0.1–0.2 mg/kg every 4 hours as needed, administered slowly. Duramorph IV adult initial range is 2–10 mg per 70 kg, individualized; its label does not assign the same every-four-hour schedule. Have resuscitation support and monitor response. The cited Hikma products specify IV administration, not IM, SC or neuraxial use.

Use only by an experienced clinician with verified catheter/needle placement and full resuscitation capability. Observe in a staffed, fully equipped setting for at least 24 hours because respiratory depression may be delayed. Neuraxial administration is generally limited to the lumbar region; repeated intrathecal injections are not recommended. Do not put Duramorph into a continuous microinfusion device.

Hospitalized assessment with lower-concentration Duramorph test doses precedes pump implantation. Observe at least 24 hours after each test dose and for several postoperative days as needed; reassess after reservoir manipulation/refill. Infumorph 10 or 25 mg/mL is too concentrated for single-dose neuraxial injection and must not be given as a single IV, IM or SC dose. These specialist initial ranges are individualized, not an outpatient pump-setting algorithm.

Oral, IV and neuraxial doses are not interchangeable milligram for milligram. Published equianalgesic ratios are approximations; no single conversion factor is appropriate for every patient or ER product. Assess prior opioid exposure, organ function and response, provide a supervised rescue plan, and reassess closely after conversion. Do not abruptly stop or rapidly reduce regular morphine in a physically dependent patient. Agree on an individualized taper with follow-up and pain/mental-health support; the oral labels explicitly reject one universal taper schedule.

Do not use with significant respiratory depression; acute/severe asthma without appropriate monitoring or resuscitative equipment; known/suspected GI obstruction including paralytic ileus; morphine hypersensitivity; or an MAOI currently or within the preceding 14 days. Selected neuraxial labels additionally prohibit use with injection-site infection, anticoagulant therapy, uncontrolled bleeding diathesis, or another condition making epidural/intrathecal administration especially hazardous. Route/concentration exclusions remain mandatory even if not listed as section 4 contraindications.

• Duramorph and Infumorph neuraxial contraindications are product and route specific.

All selected morphine labels carry boxed warnings addressing addiction/abuse/misuse, life-threatening respiratory depression, dangerous opioid/CNS-depressant combinations and neonatal withdrawal with prolonged pregnancy exposure. Oral labels also address accidental ingestion and emphasize opioid REMS education; solution labeling highlights concentration and mg/mL errors. Duramorph and Infumorph highlight neuraxial respiratory-depression monitoring and specialized administration restrictions. Read the complete warning for the dispensed formulation. Selected Actavis and Upsher-Smith ER capsules additionally carry an alcohol-interaction boxed warning: alcohol can increase exposure and cause fatal overdose.

Nausea, vomiting, constipation, dizziness, sedation and sweating are common opioid effects; itching and urinary retention are particularly relevant to neuraxial use. Serious reactions include respiratory depression, severe hypotension, anaphylaxis and interaction-related serotonin syndrome. Chronic opioid exposure can affect endocrine function and fertility. Suspected overdose requires emergency services, airway/ventilatory support and an opioid reversal agent; recurrent depression can outlast reversal, especially with ER or neuraxial delivery, so apparent initial recovery does not end observation.

Check prescription drugs, OTC products, alcohol and supplements before initiation or dose changes.

Additional systemic opioids/sedatives may produce dangerous additive respiratory effects. Neuraxial anticoagulant restrictions are explicit in the selected labels; bleeding-risk decisions require the procedural team. Do not interpret specialist monitoring as permission for a contraindicated neuraxial combination.

Hikma 2 and 4 mg/mL oral solution establishes acute-pain use at age 2–17; pediatric chronic pain and use below two are not established. Selected IR tablets establish acute use in pediatric patients ≥50 kg who can swallow tablets, not all age groups or chronic pain. Selected ER products and Hikma IV injections do not establish safety/effectiveness below 18. Duramorph/Infumorph labels do not recommend pediatric spinal use because adequate studies are lacking.

Prolonged pregnancy exposure can cause life-threatening neonatal opioid withdrawal; arrange neonatal expertise. Human data do not establish a clear major-malformation association, but animal developmental risks and neonatal respiratory depression warrant individualized assessment. Selected ER labels advise against breastfeeding. Selected oral-solution and neuraxial labels instead describe a maternal-need/infant-risk assessment; observe exposed infants for excess sleepiness, limpness and impaired breathing, and seek emergency care for these signs. Infant withdrawal can occur when maternal opioid exposure or breastfeeding stops.

Older, frail or debilitated patients need cautious low-dose initiation and slow titration. Renal failure reduces clearance and permits M3G/M6G accumulation; cirrhosis alters clearance. Selected systemic labels advise lower-than-usual starting doses, slow titration and repeated assessment of sedation, breathing and BP, rather than a universal eGFR adjustment table. Neuraxial labels warn that high systemic levels with hepatic/renal dysfunction can take days to develop; ongoing monitoring remains necessary.

Morphine is a full opioid agonist, relatively selective for mu receptors. Analgesia accompanies dose-dependent respiratory/CNS depression, reduced GI propulsion and peripheral vasodilation. Analgesic response has no fixed pharmacologic ceiling, but adverse effects constrain dosing; this does not remove formulation-specific restrictions or the Actavis fumaric-acid ceiling. Endocrine changes and physical dependence may develop with sustained exposure.

Oral bioavailability is limited and variable because of presystemic metabolism. Hepatic glucuronidation forms M3G and analgesically active M6G, predominantly cleared in urine. MS Contin’s label describes oral bioavailability around 20–40% and an effective post-IV half-life of 2–4 hours; longer terminal estimates depend on sampling. ER absorption and neuraxial delivery prolong clinical exposure and are not represented by that systemic elimination number. Different ER capsules are not automatically bioequivalent to other ER designs.

Assess pain/function goals, prior opioid exposure, sedation, respiratory status, BP, bowel/bladder function and misuse risk. Reassess after starts, titrations, conversions and interacting-drug changes; periodically consider renal/hepatic function and ongoing need. Evaluate new hyperalgesia, dysphagia, adrenal symptoms, seizures or sleep-related breathing problems. Neuraxial care additionally requires site/device checks, delayed respiratory observation, pump refill planning and monitoring for new neurologic deficits.

Confirm the exact concentration and schedule at every refill. Never share morphine, alter ER release systems, add alcohol/sedatives without review, or change/stop regular dosing independently. Avoid driving until individual effects are known. Arrange access to an appropriate overdose reversal agent, teach caregivers its instructions, and call emergency services for unresponsiveness or slow/abnormal breathing even after it is used. Discuss constipation and secure storage away from children. Prefer take-back disposal; follow the exact label/FDA disposal instructions when take-back is unavailable.

Only trained personnel may fill the correct device port using strict asepsis and the device maker’s directions. Filter ampul contents through a 5-micron or smaller microfilter; if dilution is needed, the label recommends 0.9% Sodium Chloride Injection. A pocket fill or wrong-port injection can deliver a major overdose. Avoid an empty reservoir, which can cause severe pain/withdrawal and device complications. Teach patient/caregiver device and site care before discharge; this summary does not replace the full device refill procedure.

Hikma oral solution 2 mg/mL is a clear blue-green solution; selected 100 mL bottle NDC 0054-0237-49. The selected 15 mg IR tablet is white, scored and marked 54 over 733. Package identities are examples, not stock evidence or an instruction to select medicine by color.

Selected labeled doses are morphine sulfate strengths; do not recalculate prescriptions as free-base morphine. Different release schedules and route restrictions remain in effect. Current MS Contin selected strengths are 15, 30 and 60 mg; do not present its discontinued 100/200 mg brand products as current. Other generic tablet strengths require their own label.

Hikma IR oral products and selected injections specify 20–25°C. MS Contin and Actavis ER capsules specify 25°C with 15–30°C excursions; Upsher-Smith specifies 20–25°C with those excursions. Protect oral products from moisture and follow product-specific light-resistant packaging. Selected injections require light protection, no freezing, no heat sterilization and disposal of unused single-dose contents. Keep Duramorph/Infumorph ampuls in their cartons until use. Inspect solutions as directed; do not use inappropriate discoloration or particles. Store securely and dispose of unused medicine according to the exact label.